Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 9NIH 5INDUSTRY 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 67Carcinoma, Non-Small-Cell Lung 45Lung Neoplasms 42Lymphoma 36Prostatic Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 27Uterine Cervical Neoplasms 23Central Nervous System Neoplasms 22Neoplasm Metastasis 21Fallopian Tube Neoplasms 21Colorectal Neoplasms 21Leukemia 20Neuroblastoma 17Head and Neck Neoplasms 17Rectal Neoplasms 16Brain Neoplasms 16Adenocarcinoma of Lung 16Sarcoma 15Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Colonic Neoplasms 14Burkitt Lymphoma 14Leukemia, Myeloid, Acute 13HIV Infections 13Urinary Bladder Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Multiple Myeloma 11Hodgkin Disease 11Astrocytoma 11

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has results × Carcinoma, Neuroendocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡